Legal Representation
Attorney
Robert M. Kunstadt
USPTO Deadlines
Application History
12 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 7, 2007 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Dec 7, 2007 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Mar 6, 2007 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jan 8, 2007 | OP.D | T | OPPOSITION DISMISSED NO. 999999 | Loading... |
| Jan 8, 2007 | OP.T | T | OPPOSITION TERMINATED NO. 999999 | Loading... |
| Nov 2, 2004 | OP.I | T | OPPOSITION INSTITUTED NO. 999999 | Loading... |
| Sep 14, 2004 | CFIT | O | CASE FILE IN TICRS | Loading... |
| May 11, 2004 | ETOF | T | EXTENSION OF TIME TO OPPOSE RECEIVED | Loading... |
| May 4, 2004 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 14, 2004 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| Feb 21, 2004 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 21, 2004 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Detailed Classifications
Class 005
PHARMACEUTICAL PREPARATION, NAMELY MONOCLONAL ANTIBODY FOR THE TREATMENT OF CANCER
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Design Mark
THE MARK COMPRISES THE WORDS CETUXIMAB ERBITUX AND AN ANTIBODY DESIGN (SHOWN IN STIPPLING)
Other
-
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
CETUXIMAB